Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine*

Author： Fabunmi Rosalind   Nielsen Loretta L.   Quimbo Ralph   Schroeder Brock   Misurski Derek   Wintle Matthew   Wade Ron  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.25, Iss.3, 2009-03, pp. : 777-786

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies

By Xie Lin   Wei Wenhui   Pan Chunshen   Baser Onur  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1137-1145

Informa Healthcare

Access to resources Recommend Favorite

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes

By Ray Joshua A.   Boye Kristina S.   Yurgin Nicole   Valentine William J.   Roze Stéphane   McKendrick Jan   Tucker Daniel M. D.   Foos Volker   Palmer Andrew J.  

Current Medical Research and Opinion, Vol. 23, Iss. 3, 2007-03 ,pp. : 609-622

Informa Healthcare

Access to resources Recommend Favorite

Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes

By Levin Philip   Wei Wenhui   Wang Li   Pan Chunshen   Douglas Damon   Baser Onur  

Current Medical Research and Opinion, Vol. 28, Iss. 3, 2012-03 ,pp. : 439-446

Informa Healthcare

Access to resources Recommend Favorite

Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes

By Brodows Robert G.   Qu Yongming   Johns Don   Kim Dennis   Holcombe John H.  

Current Medical Research and Opinion, Vol. 24, Iss. 5, 2008-05 ,pp. : 1395-1397

Informa Healthcare

Access to resources Recommend Favorite

All‐cause and diabetes‐related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 672-680

John Wiley & Sons Inc

Access to resources Recommend Favorite